Outcome of Radioiodine Therapy in a West African Population

Hyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nig...

Full description

Saved in:
Bibliographic Details
Main Authors: Yetunde Onimode, Alfred Ankrah, Kayode Adedapo
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167585
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850242474827579392
author Yetunde Onimode
Alfred Ankrah
Kayode Adedapo
author_facet Yetunde Onimode
Alfred Ankrah
Kayode Adedapo
author_sort Yetunde Onimode
collection DOAJ
description Hyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nigeria. This is a retrospective analysis of consecutive patients treated with RAI for primary hyperthyroidism at the National Centre for Radiotherapy and Nuclear Medicine (NCRNM) from 2008-2013, and in the University College Hospital (UCH) from 2006-2013. Cure was defined as euthyroidism or hypothyroidism occurring at 6 months post-RAI. Data were analysed using SPSS version 21 and Epi Info version, categorical data were evaluated with the Chi-square test and Fisher's exact test. 94 patients were studied, aged 20-74 years; 78 were females, and 16 were males. 38 were Ghanaian and 56 Nigerian. The presence of thyroid-associated ophthalmopathy (TAO) made cure less likely (χ2 P = 0.006, odds ratio = 0.118; 95% confidence interval, 0.027-0.518). Other factors assessed proved to be insignificant. Our findings suggest that hyperthyroid patients with TAO will benefit from a higher RAI dose than their counterparts without TAO.
format Article
id doaj-art-b616dcbf0dc8459ab4baab02088c196c
institution OA Journals
issn 1450-1147
1607-3312
language English
publishDate 2016-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series World Journal of Nuclear Medicine
spelling doaj-art-b616dcbf0dc8459ab4baab02088c196c2025-08-20T02:00:17ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122016-01-011501242910.4103/1450-1147.167585Outcome of Radioiodine Therapy in a West African PopulationYetunde Onimode0Alfred Ankrah1Kayode Adedapo2Department of Nuclear Medicine, University College Hospital, Ibadan, Oyo State, NigeriaDepartment of Nuclear Medicine, National Centre for Radiotherapy and Nuclear Medicine, Korle Bu Hospital, Accra, GhanaDepartment of Nuclear Medicine, University College Hospital, Ibadan, Oyo State, NigeriaHyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nigeria. This is a retrospective analysis of consecutive patients treated with RAI for primary hyperthyroidism at the National Centre for Radiotherapy and Nuclear Medicine (NCRNM) from 2008-2013, and in the University College Hospital (UCH) from 2006-2013. Cure was defined as euthyroidism or hypothyroidism occurring at 6 months post-RAI. Data were analysed using SPSS version 21 and Epi Info version, categorical data were evaluated with the Chi-square test and Fisher's exact test. 94 patients were studied, aged 20-74 years; 78 were females, and 16 were males. 38 were Ghanaian and 56 Nigerian. The presence of thyroid-associated ophthalmopathy (TAO) made cure less likely (χ2 P = 0.006, odds ratio = 0.118; 95% confidence interval, 0.027-0.518). Other factors assessed proved to be insignificant. Our findings suggest that hyperthyroid patients with TAO will benefit from a higher RAI dose than their counterparts without TAO.http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167585goitrehyperthyroidismnuclear medicineradioiodinewest africa
spellingShingle Yetunde Onimode
Alfred Ankrah
Kayode Adedapo
Outcome of Radioiodine Therapy in a West African Population
World Journal of Nuclear Medicine
goitre
hyperthyroidism
nuclear medicine
radioiodine
west africa
title Outcome of Radioiodine Therapy in a West African Population
title_full Outcome of Radioiodine Therapy in a West African Population
title_fullStr Outcome of Radioiodine Therapy in a West African Population
title_full_unstemmed Outcome of Radioiodine Therapy in a West African Population
title_short Outcome of Radioiodine Therapy in a West African Population
title_sort outcome of radioiodine therapy in a west african population
topic goitre
hyperthyroidism
nuclear medicine
radioiodine
west africa
url http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167585
work_keys_str_mv AT yetundeonimode outcomeofradioiodinetherapyinawestafricanpopulation
AT alfredankrah outcomeofradioiodinetherapyinawestafricanpopulation
AT kayodeadedapo outcomeofradioiodinetherapyinawestafricanpopulation